MetaVia to present Phase 1 DA-1726 data at Precision Liver Symposium
MetaVia announced acceptance for an oral presentation of Phase 1 data for dual receptor agonist DA-1726, showing potential for weight loss and liver benefits.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed